Cargando…
Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study
PURPOSE/BACKGROUND: Glycine transporter-1 inhibitors may ameliorate cognitive deficits in schizophrenia. This study evaluated potential drug-drug interactions with the glycine transporter-1 inhibitor BI 425809. METHODS/PROCEDURES: Interactions with cytochromes P450 (CYP) and P-glycoprotein (P-gp) we...
Autores principales: | Desch, Michael, Schlecker, Christina, Hohl, Kathrin, Liesenfeld, Karl-Heinz, Chan, Tom, Müller, Fabian, Wunderlich, Glen, Keller, Sascha, Ishiguro, Naoki, Wind, Sven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988221/ https://www.ncbi.nlm.nih.gov/pubmed/36700734 http://dx.doi.org/10.1097/JCP.0000000000001656 |
Ejemplares similares
-
Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor
por: Desch, Michael, et al.
Publicado: (2021) -
Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies
por: Rosenbrock, Holger, et al.
Publicado: (2018) -
Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics
por: Moschetti, Viktoria, et al.
Publicado: (2018) -
The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [(14)C]-BI 425809 in Healthy Males
por: Burkard, Ute, et al.
Publicado: (2021) -
Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [(14)C]‑BI 425809 in Healthy Males
por: Burkard, Ute, et al.
Publicado: (2022)